NCT05154344View on ClinicalTrials.gov

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)

CompletedOBSERVATIONAL
Enrollment

182

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

February 1, 2022

Conditions
MET AlterationsNon Small Cell Lung CancerMETex14 Mutations
Interventions
DRUG

Capmatinib

Available through expanded access

Trial Locations (2)

Unknown

CHU, Lille

CHU, Tours

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER

NCT05154344 - RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) | Biotech Hunter | Biotech Hunter